Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary
Therapeutic Advances in Hematology
Published online on May 19, 2026
Abstract
Therapeutic Advances in Hematology, Volume 17, January-December 2026.
SummaryWhat is this summary about?Ruxolitinib (JAKAFI®) is a Janus kinase (JAK) 1 and JAK2 inhibitor that is approved for acute and chronic graft-versus-host disease (GVHD). The phase III REACH2 and REACH3 trials tested efficacy and safety of ruxolitinib ...
SummaryWhat is this summary about?Ruxolitinib (JAKAFI®) is a Janus kinase (JAK) 1 and JAK2 inhibitor that is approved for acute and chronic graft-versus-host disease (GVHD). The phase III REACH2 and REACH3 trials tested efficacy and safety of ruxolitinib ...